Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large cohort‐study, we assessed the morbidity in 1328 Swedish CML...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahlén, Torsten, Edgren, Gustaf, Ljungman, Per, Flygt, Hjalmar, Richter, Johan, Olsson‐Strömberg, Ulla, Wadenvik, Hans, Dreimane, Arta, Myhr‐Eriksson, Kristina, Zhao, Jingcheng, Själander, Anders, Höglund, Martin, Stenke, Leif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306877/
https://www.ncbi.nlm.nih.gov/pubmed/35015312
http://dx.doi.org/10.1002/ajh.26463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306877/
https://www.ncbi.nlm.nih.gov/pubmed/35015312
http://dx.doi.org/10.1002/ajh.26463

Ejemplares similares